Congratulations to the winners of this year’s Investigator Award! Each winner receives free registration for the 8th EAN Congress in Vienna and an award certificate.
Calls for Coordinated Action on Brain Health in European Parliament on Brain Health Day
March 18, 2026
The European Parliament marked Brain Health Day: Prevention, Policy, Progress with a high‑level programme hosted by MEP Angelika Winzig, bringing renewed political attention to Europe’s urgent need for an integrated brain health strategy.
EAN 2026 Hits New All-Time Abstract Submission Record
February 13, 2026
Join us for Brain Health Day: Prevention, Policy, Progress
February 11, 2026
Latest Posts
-
-
News in generalTop Articles
World Federation of Neurology elects Prof. Wolfgang Grisold as new president
October 18, 2021On 2 October, 2021, the Council of Delegates of the World Federation of Neurology elected Prof. Wolfgang Grisold to be their next president. -
Breaking newsCOVID-19
Hemorrhagic and thrombotic manifestations in the central nervous system in COVID-19: A large observational study in the Brazilian Amazon with a complete autopsy series
October 13, 2021This study aimed to describe gross and microscopic CNS pathology findings from the autopsies and correlate them with the clinical and laboratory characteristics of 45 patients with COVID-19 from Manaus, Amazonas, Brazil. -
This study quantifies changes in neuro-oncological care during the height of the pandemic and investigates patient outcomes in 2020 compared to a historical control.
-
Breaking newsCOVID-19
The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic
October 13, 2021In this article the authors aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache. -
Breaking newsCOVID-19
Long-term neurological manifestations of COVID-19: prevalence and predictive factors
October 13, 2021From a sample of 208 consecutive non-neurological patients hospitalised for COVID-19 disease, 165 survivors were re-assessed at 6 months according to a structured standardised clinical protocol. -
Breaking newsCOVID-19
Increased risk of death from COVID-19 in multiple sclerosis: a pooled analysis of observational studies
October 13, 2021The objective of this study was to estimate whether the risk of death from COVID-19 in patients with multiple sclerosis (MS) exceeds that of the general population. -
Breaking newsCOVID-19
Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis
October 13, 2021In this article the authors reviewed all vaccine related CVT published cases by April 30, 2021. -
Breaking newsCOVID-19
Central neuroinflammation in COVID-19: a systematic review of 182 cases with encephalitis, acute disseminated encephalomyelitis, and necrotizing encephalopathies
October 13, 2021This study aims to determine the profile and possible mechanisms behind CNS inflammatory diseases in the context of COVID-19. -
Breaking newsCOVID-19
COVID-19-related headache and sinonasal inflammation: A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection
October 13, 2021This bi-center longitudinal study evaluated symptoms in consecutive COVID-19 patients in the participating practices. -
Breaking newsCOVID-19
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic
October 13, 2021In this article the authors provide an overview on BTKi mechanisms relevant to COVID-19 infection and vaccination and review preliminary data on BTKi use in patients with COVID-19. -
Breaking newsCOVID-19
Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study
October 13, 2021This Self-controlled case series study using national data on COVID-19 vaccination and hospital admissions. -
In this study the authors investigated the effect of vaccination of health care workers in Scotland on the risk of coronavirus disease 2019 (COVID-19) among members of their households.
-
Breaking newsCOVID-19
Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine through 6 Months
October 13, 2021In this ongoing trial, the authors randomly assigned 44,165 participants aged 16 or older and 2,264 participants aged 12-15 to receive two 30-μg doses, at 21 days apart, of BNT162b2 or placebo. -
EAN was able to welcome 46 participants from 15 countries - Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Romania, Russia, Spain, Tunisia, Turkey and Ukraine - to Loutraki.









